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Abstract
Background: Mental health disorders in the context of long-term conditions in children and young people are
currently overlooked and undertreated. Evidence-based psychological treatments for common childhood mental
health disorders (anxiety, depression and disruptive behaviour disorders) have not been systematically evaluated in
young people with epilepsy despite their high prevalence in this population. The aim of this multi-site randomised
controlled trial is to determine the clinical and cost-effectiveness of adding a modular psychological intervention to
usual care for the mental health disorders in comparison to assessment-enhanced usual care alone.
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Methods: In total, 334 participants aged 3–18 years attending epilepsy services will be screened for mental health
disorders with the Strengths and Difficulties Questionnaire (SDQ) and the diagnostic Development and Wellbeing
Assessment (DAWBA). Those identified as having a mental health disorder and consenting to the trial will be
randomised to either receive up to 22 sessions of the modular psychological intervention (MATCH-ADTC) delivered
over the telephone over 6 months by non-mental health professionals in addition to usual care or to assessment-
enhanced usual care alone. Outcomes will be measured at baseline, 6 months and 12 months post-randomisation. It
is hypothesised that MATCH-ADTC plus usual care will be superior to assessment-enhanced usual care in improving
emotional and behavioural symptoms. The primary outcome is the SDQ reported by parents at 6 months.
Secondary outcomes include parent-reported mental health measures such as the Revised Children’s Anxiety and
Depression Scale, quality of life measures such as the Paediatric Quality of Life Inventory and physical health
measures such as the Hague Seizure Severity Scale. Outcome assessors will be blinded to group assignment.
Qualitative process evaluations and a health economic evaluation will also be completed.
Discussion: This trial aims to determine whether a systematic and integrated approach to the identification and
treatment of mental health disorders in children and young people with epilepsy is clinically and cost-effective. The
findings will contribute to policies and practice with regard to addressing mental health needs in children and
young people with other long-term conditions.
Trial registration: ISRCTN ISRCTN57823197. Registered on 25 February 2019.
Keywords: Epilepsy, Neurology, Paediatric, Mental health, Anxiety, Depression, Disruptive behaviour, Cognitive
behaviour therapy, Teletherapy
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Background and rationale {6a}
Children and young people with epilepsy who also have
mental ill-health are poorly served by current health care
provision. The mental health disorders often go un-
detected and undiagnosed, treatment when provided is
often inadequate and service organisation fails to inte-
grate and co-locate physical and mental health care [1].
This is despite the evidence that co-occurring mental ill-
health impacts on physical health and quality of life and,
in adults, increases chance of death [2, 3].
The protocol described here is for a randomised
controlled trial (RCT) designed to address aspects of this
problem. The clinical trial forms Work Package 3 of a
broader research programme aimed at developing a new
psychological treatment for anxiety, depression and
behavioural problems in children with epilepsy.
The background and rationale for the research
programme as a whole is embedded within a wider
national priority within the UK National Health Service
(NHS) - namely the closer integration of mental and
physical health care [4]. Epilepsy is the most common
serious neurological disorder in childhood, affecting
approximately 1 in 150 children [5]. Evidence-based psy-
chological treatments for common childhood mental
health disorders (anxiety, depression and disruptive be-
haviour disorders) have not been systematically evalu-
ated in young people with epilepsy despite their high
prevalence in this population [6–9]. Although epilepsy is
defined by recurrent seizures, the comorbid mental
health disorders such as anxiety and depression often
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have a greater impact on quality of life [10]. One reason
for the failure to apply psychological treatments may be
current service organisation. Such patients are seen in
paediatric services and, if mental health input is needed,
are referred to local Child and Adolescent Mental Health
Services (CAMHS). However, CAMHS are overstretched
[11] and inexperienced in dealing with mental ill-health in
the context of a long-term condition [12].
The Modular Approach to Therapy for Children with
Anxiety, Depression, Trauma or Conduct problems
(MATCH-ADTC) is a psychological intervention which
is compliant with UK recommended best practice with
modules that are selected to treat multiple common
mental health disorders in youth [13–15]. It draws from
psychological theories to encourage positive behaviours
and reduce unhelpful ones and is based on principles of
cognitive behaviour therapy (CBT) for managing
behaviour problems, anxiety, depression and trauma in
children. The treatment contains therapeutic procedures
that were selected to correspond to the practices found
in several leading evidence-based psychological treat-
ments (EBTs), against which MATCH was compared in
randomised trials [14, 15]. Despite extensive trial litera-
ture demonstrating the efficacy of evidence-based psy-
chological treatments [16], they are disappointingly
rarely implemented in clinical practice [17]. The MATC
H-ADTC protocol and manual modular design ensures
that the needs of individuals with multiple mental disor-
ders (40% of patients) are met - in contrast to the proto-
col for the majority of trials which address only single,
specific disorders [18].
MATCH-ADTC is divided into 33 practice modules
that correspond to four focus areas with corresponding
coordinating modules. The first focus area/coordinating
module is for anxiety disorders and the practice modules
within this correspond to the strategies in ‘Coping Cat’
[19]. The second focus area is for the treatment of
depression and the modules within this corresponds to
the strategies in ‘Primary and Secondary Control
Enhancement Training’ (PASCET) [20]. The third focus
area is for Parent Training for behavioural problems
[21]. The fourth focus area is for trauma. Both Coping
Cat and PASCET have been used successfully in
children with physical illnesses and comorbid mental
health conditions [22]. According to the protocol, the
therapist focuses on the initial problem area identified
by the patient and family together with the information
gathered in the clinical and research assessment. It is
considered to represent true evidence-based practice in
that the protocol combines research evidence, clinical
judgement and patient values and preferences [23]. Once
a problem area has been selected (e.g. anxiety), an algo-
rithm specifies a default sequence of focus area and
practice modules and guides clinical judgement.
However, the intervention is also personalised so that if
the default sequence cannot be implemented (e.g. due to
low mood), then the sequence can be changed to ad-
dress the immediate issue. Once the interfering issue has
been addressed, treatment for the original problem area
is resumed. Carers and family members can join the
telephone/video conferencing sessions where appropriate
and in the original trial 41% of the sessions included the
child plus a family member [14].
Focus groups with patients and family members
identified the need for an epilepsy-specific focus area/co-
ordinating module, which was not a component of the
published MATCH-ADTC protocol. This was felt neces-
sary to meet the needs of young people with both epi-
lepsy and mental health disorders. Epilepsy-relevant
content was integrated throughout the treatment, such
as epilepsy-related examples in worksheets. The epilepsy
materials were developed and finalised in earlier stages
of the programme of research [24].
Objectives {7}
The overarching aim of this programme of research is to
transform the treatment of mental health disorders in
young people with epilepsy by systematically identifying
and treating mental health problems from within
epilepsy services to enable early detection and
intervention.
Specifically, the trial aims to determine the clinical and
cost-effectiveness of adding a personalised modular psy-
chological intervention—MATCH-ADTC with epilepsy-
relevant content integrated throughout and an additional
epilepsy-specific focus area, with one compulsory and
three optional modules—to assessment-enhanced usual
care. Assessment-enhanced usual care is usual care with
the addition of standardised assessment measures, since
those in this arm will have completed the Development
and Well-being Assessment (DAWBA) and the results
of the DAWBA will be provided to clinicians and to par-
ticipants. The intervention will be delivered by non-
mental health specialists, over the telephone/online,
within epilepsy services, for young people with epilepsy
who also meet Diagnostic and Statistical Manual of
Mental Disorders (DSM-5) diagnostic criteria for a men-
tal health disorder.
Trial design {8}
This study is a two-arm randomised controlled superior-
ity trial comparing the clinical and cost-effectiveness of
MATCH-ADTC in addition to usual care for mental
health disorders in epilepsy to assessment-enhanced
usual care alone.
Patients aged 3–18 years within epilepsy services (and
their accompanying parent/carer) will be approached.
The process of determining eligibility will involve being
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asked some brief questions, completing the Strengths
and Difficulties Questionnaire (SDQ) [25, 26] and, if
above the threshold, providing informed consent before
completing a full computerised psychiatric diagnostic
assessment (the Development and Wellbeing
Assessment: DAWBA [27]). Those meeting diagnostic
criteria for a mental health disorder according to this
assessment will be invited to take part in the trial.
Participants will be individually randomised to usual
care only or to usual care plus the MATCH-ADTC
intervention. The primary outcome measure is the total
difficulties score from the SDQ reported by the parent/
carer at 6 months post-randomisation. The primary ana-
lysis will be conducted on an intention-to treat basis and
blind to treatment assignment. All measures will be re-
peated 1 year post-randomisation to examine whether
any improvements in mental health are maintained as a
secondary outcome.
Methods: participants, interventions and
outcomes
Study setting {9}
Recruitment will be from any epilepsy clinic setting,
ranging from highly specialist to general hospitals, and
from a range of populations served. All sites are in the
UK. Therapists will be NHS staff working within
epilepsy services and will include epilepsy nurse
specialists, pre-qualification psychology assistants, neu-
rologists, neuropsychologists and support workers. A full
list of participating sites is available from http://www.
isrctn.com/ISRCTN57823197.
Eligibility criteria {10}
Participants will be considered eligible for enrolment in
this trial if they fulfil all the inclusion criteria and none
of the exclusion criteria as defined below.
Participant inclusion criteria
1. Attending NHS epilepsy clinics.
2. Aged 3–18 years.
3. Scoring above the pre-specified threshold on the
SDQ for mental health symptoms which is a com-
bination of raised total difficulty score (≥ 14) and
raised impact score (≥ 2).
4. Meeting DSM-5 diagnostic criteria for a mental
health disorder (e.g. depression, anxiety, disruptive
behaviour or trauma) identified by the SDQ, the
Development and Wellbeing Assessment (DAWBA)
and clinical assessment.
5. Have a parent/carer who is also willing to take part
in the study.
Participant exclusion criteria
1. Not speaking/understanding English sufficiently
well to access the screening assessments.
2. Having an intellectual disability at a level meaning
that they cannot access the measures or
intervention.
3. Screening results that indicate a severe mental
health disorder not considered suitable for the trial
intervention due to the clinical need for immediate
intervention, e.g. active suicidality and psychosis.
4. Actively receiving intensive psychological input
focused on cognitive and/or behavioural strategies
to intervene with emotional or behavioural
difficulties at the time of the assessment or due to
have such input during active phase of treatment.
5. Refusing to consent to the research team contacting
their general practitioner (GP)/other relevant health
professionals about their inclusion in the research.
6. Refusing to have the trial therapy sessions audio
and/or video recorded.
7. Unable to complete the measures despite all
reasonable efforts being made to assist.
Who will take informed consent? {26a}
The order of screening procedures, consent and pre-
randomisation assessments is as follows:
1. Families may be approached in clinic/hospital by a
member of the research team and asked a few brief
questions to determine their eligibility for
participation and depending on their answers to
these questions, they may be asked to complete the
SDQ. Families may also be identified by clinicians
who are familiar with them. In the latter situation,
the clinical team will make contact with the family
to ask them if they are interested in being contacted
by the MICE trial team or wish to contact the
MICE team directly. They will be asked the same
questions to establish eligibility.
2. The parent (and child) must give verbal consent to
complete the SDQ and agree to being contacted
with the results. They will be offered the choice of
completing the SDQ in clinic, online or alone in
their own time or with support (via the telephone/
online or in person).
3. Once the SDQ is completed, a member of the
research team will inform the family of the results
by telephone, letter, in person or secure email.
4. If the results of the SDQ indicate that the
participant may be suitable for the trial, the parent/
carer will be given the participant information sheet
(PIS) and Informed Consent Form (ICF). The
participant will be given an age appropriate PIS
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according to their developmental age and an ICF or
Assent Form.
5. Written informed consent will be obtained from the
parent/carer. Written informed consent or assent
will be obtained from the participant. Participants
aged 16 to 18 years must provide written informed
consent if able to do so. If a participant is aged 16
to 18 years and lacks capacity to consent for
themselves then their parent/carer should provide
written informed consent on the participants’
behalf. Participants aged under 16 years should
provide written informed assent if appropriate. The
informed consent and assent process may take
place by telephone but written informed consent/
assent must subsequently be provided to the trial
team (either by post, email or at a visit for trial
records).
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
The consent form includes consent for future contact
regarding ancillary studies, including those related to
data linkage with national datasets.
Explanation for the choice of comparators {6b}
One potential advantage of MATCH-ADTC over
existing protocols is that it can be used to treat the
significant proportion (approximately 40%) of patients
who have multiple mental health problems [18]. Other
advantages are that the intervention is designed to be
adapted for a diverse range of children, ages and
problems and can be delivered in a range of social and
healthcare services, including neurological services, by
non-mental health specialists. In addition, it can be de-
livered over the telephone or via virtual online video
platforms. The comparison against assessment-enhanced
usual care ensures that we can determine the added
value over existing service provisions.
Intervention description {11a}
Assessment-enhanced usual care
Usual care for mental health disorders varies by site but
typically includes referral to CAMHS or hospital-based
paediatric psychology services (see Fig. 1). This interven-
tion is considered as ‘assessment-enhanced’ usual care
since those in this arm will have completed the DAWBA
and the results of the DAWBA will be provided as infor-
mation to the GP, referrer and other clinical team mem-
bers involved as appropriate (e.g. neurologist or
paediatrician).
MATCH-ADTC in addition to usual care
The epilepsy-specific version of MATCH-ADTC used in
the trial is a personalised modular cognitive-behavioural
intervention with epilepsy-relevant content integrated
throughout and an additional epilepsy-specific focus
area, including an epilepsy-specific compulsory module
and three optional epilepsy-related modules delivered
over the telephone/video conferencing for young people
attending epilepsy clinics who meet diagnostic criteria
for a DSM-5 mental health disorder, in addition to usual
care.
MATCH-ADTC involves a weekly phone/online video
call with the therapist who carries out the initial face-to-
face assessment; parents complete measures at home
and email them to the therapist before each session, and
strategies are practiced at home. Face-to-face therapy
sessions are permitted if clinically indicated or strongly
preferred by the family. MATCH-ADTC comprises an
average of 16 sessions but there is flexibility as many
young people will have multiple mental health disorders
whereas others may have one. MATCH-ADTC uses an
algorithm to tailor the treatment to each young person’s
individual needs and participants with co-occurring
mental health disorders can have each of those ad-
dressed within the intervention. Those with intellectual
disabilities may need to go at a slower pace than others
and therefore may require more sessions. The minimum
number is expected to be 10 and the maximum number
of sessions is 22. The intervention must be completed
within a 6-month window. The two booster sessions
may be completed outside of this window. Some patients
may receive fewer than 10 sessions providing that there
is mutual agreement that their goals have been reached.
All therapy sessions will be delivered within 6 months of
randomisation although booster sessions can occur be-
tween 6 and 12months post-randomisation. Clinical
sessions including face-to-face sessions and telephone/
online video calls will be audio and/or video recorded
to ensure the sessions are delivered consistently. Key
content of MATCH-ADTC for depression includes
cognitive and problem-solving strategies and schedul-
ing pleasurable activities; anxiety is addressed using
exposure techniques; behavioural strategies, delivered
through the parents, include one-on-one time, praise,
effective instruction-giving, rewards and ignoring un-
wanted behaviour; trauma is addressed through devel-
oping a trauma narrative, exposure and safety
planning. Session by session measurement of symp-
toms and progress towards self-identified goals is also
included as part of the intervention.
Children and young people in the MATCH-ADTC
arm will also access usual care for the mental health
disorder if required as per Fig. 1.
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Patient public involvement (PPI)
There is a strong PPI element to the MICE trial,
including a diverse and committed research advisory
group (RAG) comprising parents, carers and young
people with epilepsy (with an age range of 6–15 years).
Meetings were held every 2 months to develop the
treatment and quarterly during the training phase and
will continue quarterly for the duration of the trial.
Several members of the group were also involved in the
advisory work for the programme development grant
which preceded the MICE trial. All adult members of
the RAG have completed modules 1 and 2 of
NIHR online PPI training and several of the group have
co-authored a paper on patient experiences which has
been submitted for publication. The PPI lead was part of
the interview panel which recruited two research assis-
tants to the project and has co-presented at an event
with the PI about the impact of high-quality PPI. The
Steering Group also has two independent PPI represen-
tatives with lived experience. The goals of the PPI group
are to ensure that the trial meets the needs of the popu-
lation it is intended to serve.
Criteria for discontinuing or modifying allocated
interventions {11b} –
In consenting to the trial, participants are consenting to
trial treatment, trial follow-up and data collection. How-
ever, an individual participant may stop treatment early
or be stopped early for any of the following reasons:
 Unacceptable serious adverse event
 Inter-current illness that prevents continuing the
trial intervention
Fig. 1 Usual care for mental health disorders in children and children and young people with epilepsy
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 Any change in the participant’s condition that in the
clinician’s opinion justifies the discontinuation of the
trial intervention
 Withdrawal of consent for the trial intervention by
the participant
As participation in the trial is entirely voluntary, the
participant may choose to discontinue trial treatment at
any time without penalty or loss of benefits to which
they would otherwise be entitled.
Training and supervision of therapists
Professionals from a range of backgrounds (including
consultant paediatricians, paediatric nurses, assistant
psychologists and epilepsy nurse specialists) were trained
over a 6-month period to deliver the mental health
intervention. Training included a 5-day intensive train-
ing led by experts in the field of epilepsy and mental
health, including members of the MATCH-ADTC team,
epilepsy experts and mental health professionals with ex-
tensive experience in working with children, young
people and families. Therapists received a half-day
booster training at the end of the 6-month period with
topics tailored to their individual training needs. All
therapists saw at least one family for telephone-delivered
mental health treatment during the 6-month training
period during which therapists were offered weekly tele-
phone clinical supervision with a qualified clinical psych-
ologist. Supervision-of-supervision was provided on a
monthly basis by a member of the MATCH-ADTC
team.
Strategies to improve adherence to interventions {11c}
Therapist competence will be assessed using the same
methods as successfully applied to earlier studies of
MATCH-ADTC. Fidelity and competence will be
established by expert review of 10% of the sessions
selected at random by a BABCP-accredited therapist and
rated using the Cognitive Therapy Rating Scale Revised
(CTS-R) and in accordance with the principles of
MATCH-ADTC [28, 29] throughout the duration of the
trial. In addition, 10% of these will be selected at random
and double-rated by an external expert in the USA who
has been accredited by the developers of the intervention
as a supervisor and trainer.
Relevant concomitant care permitted or prohibited
during the trial {11d}
Participants who are currently actively receiving
intensive psychological input focused on cognitive and/
or behavioural strategies to intervene with emotional or
behavioural difficulties, or due to have such input within
6 months of randomisation, will not be included in the
trial.
Provisions for post-trial care {30}
There are no plans for ancillary or post-trial care. Any
significant risk issues will be communicated to the fam-
ilies’ GP and any other clinician involved in their care.
Referrals or requests for referrals to other services may
be made as appropriate.
Cover for negligent harm will be provided by the
Great Ormond Street Hospital for Children (GOSH)
NHS Foundation Trust through the Clinical Negligent
Scheme for Trusts (CNST) and University College
London (UCL).
Participants may also be able to claim compensation
for injury caused by participation in this clinical trial
without the need to prove negligence on the part of the
sponsor or another party. Participants who sustain injury
and wish to make a claim for compensation should do
so in writing in the first instance to the Chief
Investigator (CI), who will pass the claim to the
sponsor’s office.
Hospitals selected to participate in this clinical trial
shall provide clinical negligence insurance cover for
harm caused by their employees and a copy of the
relevant insurance policy or summary shall be provided
to UCL, upon request.
Outcomes {12}
Primary outcome
The primary outcome measure is the total difficulties
score from the Strengths and Difficulties Questionnaire
(SDQ) [25, 26] reported by the parent/carer at 6 months
post-randomisation. The SDQ is a brief behavioural
screening questionnaire for children and young people
aged 2 years and above. The 25 items are divided be-
tween 5 scales (emotional, conduct problems, hyper-
activity/inattention, peer relationship problems,
prosocial behaviour), with the first four added to provide
a total difficulties score. The SDQ has good internal
consistency (mean Cronbach α .73), cross-informant
correlation (mean 0.34), and retest stability after 4 to 6
months (mean 0.62) [30]. SDQ scores above the 90th
percentile predict a substantially raised probability of in-
dependently diagnosed psychiatric disorders (mean odds
ratio 15.7 for parent scales) [30]. It has been validated
across the age range of children and young people seen
within neurology clinics and used in those with autism
spectrum disorder [31] and intellectual disabilities [32]
known to be highly prevalent in this group [33]. Further,
the SDQ has an ‘impact scale’, which assesses the impact
that symptoms have on everyday life in a range of do-
mains (home, school, leisure). The parent-reported
measure was chosen for data completeness, as the self-
report version is unsuitable for young people under the
age of 11 years.
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Secondary outcomes
 Revised Child Anxiety and Depression Scale (RCAD
S) [34]. This 47-item questionnaire is one of the
main outcome measures used in the Children and
Young People’s Improving Access to Psychological
Therapies (CYP-IAPT) Programme. It is included to
allow comparison with this national initiative and
has parent and child versions, the subscales are reli-
able (Cronbach α .78–.88) and the measure has dis-
criminant, convergent and factorial validity in a
clinical sample [35]. For the trial, the parent version
will be used for data completeness.
 Patient Health Questionnaire (PHQ-9) [36]. This is a
9-item measure of depression in adults completed
by the parent/carer about their own mental health.
 Generalised Anxiety Disorder Assessment (GAD-7)
[37]. This is a 7-item measure of generalised anxiety
disorder, completed by the parent/carer about their
own mental health.
 Hague Seizure Severity Scale (HASS) [38]—this is a
parent-report questionnaire which rates carers’ sub-
jective experiences of the severity of their child’s sei-
zures. Items are statements, which are rated on a 4-
point scale from most to least severe (e.g. ‘always’,
‘usually’, ‘sometimes’ or ‘never’). Items describe the
length, type and outcomes of a seizure—for example
‘how long do the jerks or cramps last during an
attack?’
 Paediatric Quality of Life Epilepsy Module (PedsQL)
[39]. The PedsQL measures the impact of epilepsy
on quality of life.
 Number of serious adverse events. Serious adverse
events are those that result in death, are life
threatening, require hospitalisation or prolong
existing hospitalisation, result in persistent or
significant disability or incapacity, or result in a
congenital anomaly or birth defect or another
important medical condition.
Health economic measures
The following measures will be reported by the parents:
CA-SUS—Service use measured using the Child and
Adolescent Service Use Schedule, developed and applied
in a range of populations of young people with mental
health problems [40, 41].
CHU-9D—Child Health Utility 9-dimensions [42].
This is a paediatric health-related quality of life measure
for use in economic evaluation.
EQ-5D-5L—EuroQol 5-dimensions, 5-level version
[43–46]. The 5-level EQ-5D comprises 5 dimensions
(mobility, self-care, usual activities, pain/discomfort and
anxiety/depression) and will be used to assess the
health-related quality of life of the main parent/carer.
Additionally, indirect (non-face-to-face) time spent on
different activities in a typical week will be estimated by





The sample size is 334 children and young people with
epilepsy, and their parents /carers.
Previous effect size (ES; standardised magnitude of the
effect) estimates for MATCH-ADTC using measures
comparable to the SDQ range from 0.51 to 0.65 [14, 15].
Previous published research has estimated the ES for
usual care in UK CAMHS to be 0.16–0.2 [47]. We have
therefore conservatively based our calculation on an
ES = 0.3 which is modest for a psychological intervention
study. Our small pilot study comparing the guided self-
help psychological intervention against a waitlist control
found a large effect size.
A total sample size of 334 children has been chosen as
this could detect an effect size of 0.3 for the SDQ, at the
5% significance level with 80% power, assuming an
average of 14 children per therapist, an intraclass
correlation coefficient (ICC) of 0.01 for therapist effects,
a correlation of 0.5 between baseline and follow-up
SDQ, and a loss to follow-up rate of 10%. We will take
steps to minimise the amount of missing data. A gener-
alised mixed model will be used to analyse the primary
outcome adjusting for baseline SDQ and minimisation
variables.
Recruitment {15}
Clinicians can directly refer potential participants to the
study. As research has demonstrated that mental health
disorders are frequently not detected in children with
epilepsy, the study also includes a screening component
in which all patients attending epilepsy clinics and
meeting inclusion criteria will be invited to complete
screening measures and proceed further with the study
according to the results of this screening. Please see
section on informed consent for further details.
Assignment of interventions: allocation
Sequence generation {16a}
Patients will be randomised in a 1:1 ratio to MATCH-
ADTC plus usual care or to assessment-enhanced usual
care alone, using an independent web-based online sys-
tem (https://www.sealedenvelope.com). Randomisation
will use a minimisation algorithm incorporating a ran-
dom element, stratifying using the following factors:
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 Primary mental health disorder—anxiety/depression/
disruptive behaviour/trauma
 Presence of autistic spectrum disorder or
autism—yes/no
 Age—< 11/11+
 Presence of intellectual disability—yes/no
Primary mental health disorder and the presence
of autism spectrum disorder will be decided
according to the results of the DAWBA. Presence of
intellectual disability will be self-reported by parents
at baseline; this self-report will be considered in the
context of scores on the Vineland Adaptive Behav-
iour Scales (VABS) [48] at 6 months post-
randomisation. These factors were chosen due to the
high associations between epilepsy and autism
spectrum disorder and intellectual disability [49] and
the desire to have equal proportions of primary
mental health disorder and ages in the two treat-
ment allocations. Each patient will be randomised
using their unique participant identification number
that was allocated sequentially at screening. Eligibil-
ity and consent will be verified before each patient is
randomised.
Concealment mechanism {16b}
The allocation will be concealed prior to assignment to
prevent allocation bias.
Implementation {16c}
Eligibility and consent will be confirmed before each
participant is randomised.
Assignment of interventions: blinding
Who will be blinded {17a}
Trial participants, their parent/carer, therapists and the
MICE study team will be unblinded to treatment allocation.
Participant outcome assessments at 6 months (the
primary endpoint) and 12months will be carried out by
an independent researcher blind to treatment allocation.
The final analysis will be performed by a blinded statistician.
An unblinded statistician at the Comprehensive Clinical Trials
Unit at UCL (CCTU) will prepare any sections of reports for
the data monitoring and ethics committee (DMEC) in which
data is presented by treatment arm.
Health economic analysis cannot be undertaken blind
because the analysis requires the intervention cost to be
applied to those young people in the intervention group.
However, health economic analysis results will be
presented to and interpreted by the Programme
Management Group blind to allocation (i.e. results will
be presented as group A versus group B).
Procedure for unblinding if needed {17b}
This is not needed as trial participants, their parent/
carer, therapists and the MICE study team will be
unblinded to treatment allocation.
Table 1 Participant timeline for assessment and measure completion
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Data collection and management
Plans for assessment and collection of outcomes {18a}
Each participant will be given a unique trial participant
identification number (PIN). Data will be collected at
the time-points indicated in the participant timeline.
All data will be entered on the database either by
parents/carers, by members of staff delegated to work on
the trial within each research site or members of the
MICE trial team based at GOSH ICH. The preferred
method of data collection is for data to be entered
directly into the Sealed Envelope database (www.
sealedenvelope.com). It will be possible for parents/
carers to self-complete some forms directly on the data-
base. Investigators will be able to use the database to
send an email or text message link to invite parents/
carers to self-complete relevant forms. If self-completion
online is not possible, site staff can ask the parents/
carers the questions by telephone and enter the data dir-
ectly. If this is not possible, then parents/carers are able
to complete paper forms/questionnaires which can then
be entered on to the database by site staff.
Paper worksheets will be provided as aides for data
collection; however, the completion of these is optional.
Completion of the worksheets may be helpful if a
computer is not readily available to ensure all required
data is collected. If data is collected on paper
worksheets, e.g. from clinical studies officers, data entry
will be performed as soon as possible by a member of
the MICE study team. We will record whether data were
collected directly from the participant or whether it was
entered by a member of the MICE study team.
Data collection, data entry and queries raised by a
member of the MICE trial team will be conducted in
line with the CCTU and trial specific Data Management
Plan.
Clinical trial team members will receive trial protocol
training. All data will be handled in accordance with the
General Data Protection Regulation and UK Data
Protection Act 2018.
Data management {19}
Data will be entered using the participant’s PIN onto a
central database hosted by the third-party organisation
Sealed Envelope. The database will be password pro-
tected and only accessible to parents/carers and partici-
pants (where appropriate), delegated members of site
staff and the MICE trial team, and external regulators if
requested.
The Sealed Envelope database is hosted on servers in
the UK provided by Rackspace UK; these servers are
backed up by Amazon Web Services Ireland (AWS), and
both Rackspace UK and AWS have been certified to ISO
27001 and ISAE 3402. Access to the database is
controlled by password-protected accounts, and an
individual’s access to the database is restricted by their
role. The underlying database infrastructure is encrypted
and access is strictly limited to Sealed Envelope staff.
The database and metadata have been developed by
the clinical trial manager in conjunction with CCTU.
The database software provides a number of features to
help maintain data quality, including maintaining an
audit trail, allowing custom validations on all data,
allowing users to raise data query requests and reports
to identify validation failure/missing data.
The identification, screening and enrolment logs,
linking participant identifiable data to the
pseudoanonymised PIN, will be held locally by the trial
site. This will either be held in written form in a locked
filing cabinet or electronically in password-protected
form on hospital computers. After completion of the
trial, the identification, screening and enrolment logs
will be stored securely by the sites for 10 years unless
otherwise advised by CCTU.
Plans to promote participant retention and complete
follow-up {18b}
The importance of attending scheduled therapy sessions
and follow-up visits until trial completion will be ex-
plained to all participants at the start of the trial to en-
sure that only those able to commit to the protocol are
recruited. Participants who discontinue protocol treat-
ment should remain in the trial for the purpose of
follow-up and data analysis. They will be asked whether
they continue to consent to being contacted for follow-
up assessments. Data will be analysed on an intention-
to-treat (ITT) basis. Therefore, withdrawal from the
study will not result in exclusion of the data for that par-
ticipant from analysis. Participants who are randomised
but discontinue trial treatment or withdraw from the
trial will not be replaced.
Confidentiality {27}
Patient identifiable data, including initials, and date of
birth will be required for the registration process. The
study staff will ensure that the participants’ anonymity is
maintained, except where information is disclosed by a
patient or parent/carer that suggests a risk of harm to
the patient, parent/carer or others. Each participant will
be assigned a unique 5-digit trial PIN by site staff. The
database will record the PIN, the patient’s initials and
date of birth, but not the patient’s name. The only link
between the PIN and the patient’s name will be on the
screening log kept at site and accessed only by the pa-
tient’s direct clinical care team. Data will be recorded on
the custom-designed Sealed Envelope database under
this identification number. The database will be pass-
word protected and only accessible to members of the
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MICE trial team at CCTU, trained and authorised site
staff, and external regulators if requested.
All documents will be stored securely and only
accessible by study staff and authorised personnel. The
study will comply with the Data Protection Act, which
requires data to be anonymised as soon as it is practical
to do so.
Data will be stored in a secure manner and in
accordance with the Data Protection Act 2018.
The research team will have access to participants’
medical records (including their hospital records).
Access to participants’ medical history and to files to
write summary notes of progress will be necessary.
Access to medical records by those outside of the direct
healthcare team will only be gained after the participant/
parent/carer has given their consent for this.
Participants’ educational records may also be accessed
by the research team. Consent will be taken for
potentially linking data collected to Health Episode
Statistics and the National Pupil Database.
Postal and email addresses will be required to write to
participants (for example to send them progress reports
or to send them electronic copies of measures). Phone
numbers and/or usernames/addresses will be required
for telephone/video conferencing consultations as part
of the intervention, possibly for interviews and
assessments and to provide support in completing
measures and to send text messages. The research team
will only have access to these details if the participant
has consented to this, and such data will be held at
Great Ormond Street Hospital. All phone/video
conference calls and face-to-face meetings, including as-
sessments, interviews and clinical sessions, will be audio/
video recorded. Only therapists will be shown on video
recordings.
Audio recording of some participants’ assessment
interviews will be transcribed verbatim and used for the
purposes of qualitative analysis. Quotes from these
interviews may be used to illustrate presenting themes,
but any data that would make the participant identifiable
would be removed. Telephone calls will also be audio
recorded, for use in supervision and to ensure fidelity to
the protocol. Video recordings of clinical sessions may
also be made. Only therapists will be shown on video
recordings. Personal data will be contained within a
project master file (paper copy), which will be kept in a
locked cabinet accessible only to the research team at
GOSH. Personal data contained on research databases
(for example participant contact addresses) will be kept
on a secure, restricted-access drive, only accessible to
the research team with GOSH contracts.
All other electronic information pertaining to the trial
will be kept in encrypted, password-protected files
stored on the GOSH internal network (including GOSH
laptops). In the event of a sponsor-led audit or inspec-
tion, the authorised research and development (R&D)
individual will also require access to the participant’s
medical and educational records in the course of their
duties.
Statistical methods
Statistical methods for primary and secondary outcomes
{20a}
Patient characteristics at the time of randomisation will
be summarised using mean and SD for continuous
variables which are approximately normally distributed,
median and interquartile range (IQR) for variables which
are not normally distributed, or by frequencies and
percentages for categorical variables. All statistical
hypothesis tests will use a two-sided p value of 0.05 un-
less otherwise specified. All confidence intervals (CIs)
presented will be 95% and two-sided. All statistical ana-
lysis will be performed using Stata (StataCorp, College
Station, TX, USA) or an alternative package.
Primary outcome
The primary outcome is the difference between the
intervention group and the control group in the total
difficulties score of the parent-reported SDQ at 6 months
post-randomisation.
The total difficulties score of the SDQ has a range of
0–40. Mixed effect linear regression will be used to
determine if there is any difference in the total
difficulties score due to intervention. The model will
include fixed effects for intervention group, baseline
SDQ total difficulties score and the stratification factors;
age (< 11 versus 11+), primary mental health disorder
(anxiety, depression, disruptive behaviour or trauma),
presence of autistic spectrum disorder (yes/no) and
presence of intellectual disability (yes/no). A random
factor, Therapist, will be included to take account of
therapist effects. Results will be presented as adjusted
treatment effect and the associated 95% CI. If the
intervention is effective, we would expect to see a
reduction in the total difficulties score (higher total
difficulties score indicates a higher risk of a diagnosis of
mental illness).
The primary analysis will be conducted following the
intention-to-treat principle in accordance with the ran-
domised intervention. All efforts will be made to ensure
that the primary outcome data is collected for all pa-
tients, whether or not they complete their randomised
treatment. Missing baseline data are not anticipated
since baseline data are completed prior to randomisation
and must be recorded to allocate treatment. All patients
with reported outcome data will be included in the ana-
lysis. The primary analysis is likelihood based and there-
fore robust to the assumption of missing-at-random, but
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should substantial missing data be encountered, reasons
for missingness will be explored and a sensitivity analysis
will be undertaken to investigate the validity of the miss-
ing at random assumption.
Secondary outcomes
Separate analyses will be performed for outcomes at 6
months and at 12 months.
The timing of the primary effectiveness outcome at 6
months is because we expect to see the maximum
benefit of treatment at this time point. However, we will
be following up the children and the difference at 12
months is a secondary outcome.
Models for all secondary efficacy outcomes will be
adjusted for the stratification factors.
Binary secondary outcomes will be analysed using
mixed effects logistic regression, ordinal secondary
outcomes with mixed effects ordinal logistic regression,
and continuous secondary outcomes with mixed effects
linear regression.
Fisher’s exact test will be used to compare the
proportion of children with any serious adverse events
in the two randomised groups.
Economic analysis
A detailed health economic analysis plan, including a
full specification of the analysis principles and details,
will be written prior to the first substantive analysis and
approved in advance by the programme steering
committee (PSC).
Costs and cost-effectiveness will be compared between
groups at the final 12-month follow-up to capture the
economic impact over the longest period available. A
secondary analysis at the 6-month follow-up will be car-
ried out for consistency with the primary clinical ana-
lysis; however, to avoid unblinding the analyst earlier
than necessary, this will be carried out after the primary
economic analysis has been completed.
The economic perspective will be that of the NHS and
personal social services sectors including those provided
within the education sector. Health and social care
service use will be collected using the CA-SUS at base-
line (covering the previous 3 months) and at the 6- and
12-month follow-up points (covering the period since
last interview) using the CA-SUS. Service use will be val-
ued using nationally applicable unit costs (NHS Refer-
ence Costs and Personal Social Service Research Unit
(PSSRU) Costs of Health and Social Care). The interven-
tion will be directly costed taking a bottom-up (micro-
costing) approach and using data on direct contacts re-
corded in clinical records. Indirect (non-face-to-face)
time will be estimated using a questionnaire completed
by therapists on time spent on different activities in a
typical week. Intervention costs will be estimated using
information on therapist salaries and working condi-
tions, including relevant overhead costs (capital, man-
agerial, administrative, etc.).
As a result of current limitations in the measurement
of health-related quality of life in young children, cap-
able of generating quality-adjusted life years (QALYs)
for application in a cost-utility analysis, our primary eco-
nomic analysis will be a cost-effectiveness analysis using
the primary clinical outcome measure (parent-reported
SDQ total difficulties score).
A more exploratory secondary economic analysis will
consider cost-utility analysis using the CHU-9D to generate
QALYs. Parents of all participants will be asked to proxy-
complete the CHU-9D on behalf of all young people.
Additionally, self-report health-related quality of life
data will be collected for the main parent/carer using
the EQ-5D-5L to explore the impact of the intervention
on both young people and their carers.
Cost-effectiveness will be assessed using the net
benefit approach and following standard approaches
[50]. A joint distribution of incremental mean costs and
effects for the two groups will be generated using
nonparametric bootstrapping to explore the probability
that each of the treatments is the optimal choice, subject
to a range of possible maximum values (ceiling ratio)
that a decision-maker might be willing to pay for an
additional unit of outcome gained. Cost-effectiveness ac-
ceptability curves will be presented by plotting these
probabilities for a range of possible values of the ceiling
ratio [51]. These curves are a recommended decision-
making approach to dealing with the uncertainty that
exists around the estimates of expected costs and ex-
pected effects associated with the interventions under in-
vestigation and uncertainty regarding the maximum
cost-effectiveness ratio that a decision-maker would con-
sider acceptable.
All economic analyses will be adjusted for co-variates
in line with the clinical analyses described above, includ-
ing the stratification variables (age (< 11 versus 11+), pri-
mary mental health disorder (anxiety, depression,
disruptive behaviour or trauma), presence of autistic
spectrum disorder (yes/no), presence of intellectual dis-
ability (yes/no) and for the baseline values of the vari-
ables of interest (e.g. baseline cost, CHU-9D score, as
appropriate).
Interim analyses {21b}
No interim analyses are planned by the trial team (TT).
Regular reports will be provided to the DMEC members.
Methods for additional analyses (e.g. subgroup analyses)
{20b}
Planned subgroup analyses will be conducted to
investigate whether the effect of treatment varies
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between patients with regard to each of the stratification
factors. This will be explored by adding an interaction
between each of the factors and treatment to the
primary outcome analysis model separately.
Potential mediators and moderators will also be explored.
Further details on potential factors and the appropriate
analysis methods will be considered in the SAP.
Methods in analysis to handle protocol non-adherence
and any statistical methods to handle missing data {20c}
The main analysis will be conducted following the
intention-to-treat principle in accordance with the rando-
mised intervention. All patients with outcome data will be
included in the analysis. The primary analysis is likelihood
based and therefore robust to the assumption of missing
at random, but should substantial missing data be encoun-
tered, reasons for this will be explored and a sensitivity
analysis will be undertaken to investigate the validity of
this missing at random assumption. If the missing at ran-
dom assumption appears reasonable and the loss to
follow-up rate is as anticipated, then we would not use
multiple imputation. However, this will be considered in
detail in the statistical analysis plan (SAP).
Plans to give access to the full protocol, participant level-
data and statistical code {31c}
The Chief Investigators, Clinical Project Manager, Trial
Manager, Statistician, Health Economist and Trial
Management Team will have full access to the trial data.
Oversight and monitoring
Composition of the coordinating centre and trial steering
committee {5d} –
The composition and terms of reference of committees
are available on request from the Chief Investigators.
Trial Team (TT)
The MICE TT will be responsible for the day to day
management of the trial, including operational issues
and budget management.
Coordinating Centre
The CCTU at UCL act as coordinating centre for the
trial, providing specialism in trial design, conduct and
statistics. CCTU will also be responsible for monitoring
activities undertaken on behalf of the sponsor.
Programme management group
A programme management group (PMG) assists with
developing the design, co-ordination and strategic man-
agement of the trial.
Programme steering committee
The PSC is the independent group responsible for
oversight of the trial in order to safeguard the interests
of trial participants. The PSC provides advice to the CI,
CCTU, the funder and sponsor on all aspects of the trial
through its independent Chair.
Composition of the data monitoring committee, its role
and reporting structure {21a}
The independent data monitoring and ethics committee
(DMEC) is the only oversight body that has access to
accumulating comparative data. The DMEC is
responsible for safeguarding the interests of trial
participants, monitoring the accumulating data and
making recommendations to the PSC on whether the
trial should continue as planned. The membership,
frequency of meetings, activity (including review of trial
conduct and data) and authority will be covered in the
DMEC terms of reference. The DMEC will consider
data in accordance with the statistical analysis plan and
will advise the PSC through its Chair. The composition
and terms of reference of the DMEC are available on
request from the Chief Investigators.
Adverse event reporting and harms {22}
For the purposes of the MICE trial, only serious adverse
events will be reported. All serious adverse events
(SAEs) occurring during the trial observed by the
investigator or reported by the participant, whether or
not attributed to the trial treatment will be recorded on
the database. Low-grade adverse events that do not meet
the seriousness criteria will not be reported, for example
a grade 1 or 2 epileptic seizure that does not result in
hospitalisation.
Investigators should notify CCTU immediately and
within 24 h at the latest of any SAEs occurring from the
time of randomisation until 30 days after the participant
completes trial treatment. From this point forward, the
site will notify the CCTU of SAEs that are considered
related to the trial intervention if they become aware of
them until end of follow-up.
Participants must be followed up until clinical
recovery is complete, or until the event has stabilised.
Follow-up should continue after completion of trial
treatment and/or trial follow-up if necessary. Follow-up
SAE forms (clearly marked as follow-up) should be com-
pleted and emailed to CCTU as further information be-
comes available. Additional information and/or copies of
test results, etc., may be provided separately.
Medically qualified staff appointed by the sponsor will
review all SAE reports received. The reviewer will
complete the assessment of expectedness.
SAEs that are considered to be related to the trial
(resulted from administration of any of the research
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procedures) and unexpected must be reported to the
REC and DMEC. If the related and unexpected event is
fatal or life threatening, it must be reported within 7
days of becoming aware of the event; other related and
unexpected events must be reported within 15 days.
A list of expected occurrences as a result of the trial
treatment is as follows:
– Significant deterioration in behaviour
operationalised as consistent decline for three
consecutive weeks, over four measurement time
points, of at least 5 points for relevant behaviour
based goals (e.g. as a result of an ‘extinction burst’)
– Significant deterioration in anxiety operationalised as
consistent decline for three consecutive weeks, over
four measurement time points, of at least 5 points
for relevant anxiety-based goals (e.g. as a result of
exposure to feared situations)
– Significant deterioration in mood operationalised as
consistent decline for three consecutive weeks, over
four measurement time points, of at least 5 points
for relevant mood-based goals (e.g. as a result of
cognitive challenging)
Where the SAE falls outside of this list, it must be
deemed to be unexpected by the clinical reviewer.
CCTU will keep investigators informed of any safety
issues that arise during the course of the trial.
Frequency and plans for auditing trial conduct {23}
CCTU staff will review data entered on the database for
errors and missing key data points. The trial database
will also be programmed to generate reports on errors
and error rates. Data quality issues will regularly be
communicated to the TT. Essential trial issues, events
and outputs, including defined key data points, will be
detailed in the MICE trial Data Management Plan.
The frequency, type and intensity of routine and
triggered on-site monitoring conducted by CCTU on be-
half of the sponsor will be detailed in the MICE Quality
Management and Monitoring Plan (QMMP). The
QMMP will also detail the procedures for review and
sign-off of monitoring reports.
Plans for communicating important protocol
amendments to relevant parties (e.g. trial participants,
ethical committees) {25}
The CCTU ensure that the current trial protocol,
patient information sheet, consent form, GP letter and
submitted supporting documents have been approved by
the REC and site R&D departments prior to use in
patient recruitment. The protocol and all agreed
substantial protocol amendments will be documented
and submitted for ethical approval prior to
implementation. Where changes are planned to patient-
facing documentation, PPI groups will be consulted in
advance for input.
Dissemination plans {31a}
The dissemination plans follow best-practice recommen-
dations. The plan is to engage with policy-makers, pa-
tients, carers, the public and media contacts to
disseminate the findings across the public and private
sectors and charities. We plan to publish the findings in
peer-reviewed journals, and at national and international
conferences. We will work with professional colleges,
funders, the Epilepsy 12 national audit group and our
PPI group to disseminate the findings widely to all stake-
holders via traditional and social media.
Response to COVID-19
The COVID-19 pandemic may have a significant impact
on the mental health of participants. We therefore plan
to ask a series of questions at 6 and 12months post-
randomisation to understand how participants and their
families have been affected in order to help provide con-
text to the findings of the study.
Discussion
This protocol sets out the rationale and methods for
evaluating the impact of adding a modular psychological
intervention to usual care for young people with mental
health disorders in the context of epilepsy. The
psychological intervention will be delivered by non-
mental health specialists from within epilepsy services in
order to facilitate the closer integration of physical and
mental health care. Given the high rates of mental health
disorders coupled with high rates of unmet need in this
group, positive results could result in suggestions for
changes in service organisation and delivery in the UK
and internationally. The model could also be used for
the treatment of mental health disorders in children with
other long-term conditions.
Trial status
This manuscript presents the current version (4.0 of
27th July 2020) of the MICE Protocol. Recruitment
commenced in May 2019. It was originally expected to
be completed by May 2021 but due to delays resulting
from the COVID-19 pandemic, is now anticipated to be
completed by May 2022.
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